In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.
In the week ending June 9, 2017, the Health Care Select Sector SPDR Fund (XLV) saw a rise of 0.13%.
Medtronic’s (MDT) Tyrx envelope is an antibacterial and fully-absorbable device that helps prevent surgical site infections.
On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.
In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
For fiscal 2017, Align Technology (ALGN) expects its 2017 revenues to grow operationally in the range of 15%–25% YoY.
Align Technology (ALGN) is a medical device provider focused on malocclusion or teeth misalignment condition.
In 1Q17, Align Technology’s (ALGN) Invisalign sales volumes in North American markets rose YoY by 20.3% and QoQ by 8.3%.
For 1Q17, Align Technology (ALGN) reported revenues close to $310.3 million, which represents YoY (year-over-year) growth of around 30.0%.
Ionis Pharmaceuticals’s (IONS) volanesorsen is a drug designed to reduce apolipoprotein C-III production and triglycerides in patients with dyslipidemia. Akcea Therapeutics, a wholly owned subsidiary of Ionis, is engaged in…
As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. In April 2017, Ionis entered into…
Ionis’s (IONS) Spinraza (nusinersen) is a drug designed for the treatment of patients with SMA (spinal muscular atrophy). SMA is a severe genetic disease affecting the nervous system and voluntary…
Previously, we looked at Ionis Pharmaceuticals’ (IONS) valuation after 1Q17. In this part, we’ll discuss its revenue. The above chart shows the company’s revenue trends over the last few quarters. Ionis’s revenue…
Ionis Pharmaceuticals (IONS) reported revenue of $110.3 million in 1Q17, 200% higher than its revenue of $36.9 million in 1Q16. Analysts estimate that its revenue will increase by over 100%…
In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.
Baxter International consistently provided value to its shareholders through timely share buybacks, dividend payments, and investment in strategic M&As.
On June 7, 2017, Baxter International announced FDA approval and the commercial launch of its Clindamycin injection in saline.
Baxter International (BAX) reported its 1Q17 earnings on April 26, 2017. It reported adjusted diluted EPS of $0.58, which represents an ~61% rise YoY.